polatuzumab vedotin + cytarabine + etoposide

Polatuzumab vedotin + cytarabine + etoposide is a combination chemo-immunotherapy regimen developed by New York Medical College for the treatment of pediatric and young adult patients with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL). This regimen is part of the RADICAL clinical trial, which aims to reduce the toxicity and radiation exposure associated with standard treatments. Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate (ADC) that delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) specifically to B-cells. Cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis by competing with cytidine for incorporation into DNA and inhibiting DNA polymerase. Etoposide is a semisynthetic derivative of podophyllotoxin that acts as a topoisomerase II inhibitor, leading to DNA double-strand breaks and cell cycle arrest.

Other names

Pv-Cytarabine + etoposide